Latest Partnerships News

Radiopharm says the FDA has provided a clear framework for the pivotal development of RAD101, its investigational brain metastases imaging agent. The company is preparing for Phase 3 while awaiting formal meeting minutes that could still refine the trial design and regulatory requirements.

Aurora Labs has appointed Andrew Garth as chief executive, moving former CEO Rebekah Letheby into a newly focused chief operating role. The reshuffle is intended to separate commercial strategy from technical execution as the company pursues scaled manufacturing and defence opportunities.

FlexiRoam has onboarded one of Australia’s four major banks to offer complimentary global data roaming on premium rewards Mastercard cards. The live program is expected to generate about USD 140,000 a year under management’s current planning case, although there is no minimum revenue commitment.

AdAlta and Shanghai Cell Therapy Group have approved the FDA briefing pack and manufacturing transfer plan for EW-001, bringing the mesothelioma CAR-T therapy closer to an Australian Phase 1 trial. The FDA meeting is scheduled for November, while two Chinese patients remain under follow-up, including a second complete responder.

CSL has secured an exclusive agreement to co-develop and co-promote Alentis Therapeutics’ investigational drug lixudebart, committing US$355 million upfront and funding a multi-trial development programme. The antibody remains unapproved, with its commercial potential dependent on results from ongoing and planned clinical studies.

First Graphene has signed a three-year agreement with Turkish manufacturer Aeropreg to develop and potentially commercialise PureGRAPH-enhanced carbon fibre prepreg. The partnership offers a clearer route into aerospace, defence and automotive supply chains, but commercial launch remains dependent on trial results.

Locality Planning Energy has signed three utility infrastructure agreements that will add approximately 750 electricity and water service points across Victoria and Queensland. The expansion requires about $1.28 million of LPE-funded investment, but revenue will build only as homes, connections and retail tenancies come online.

Optiscan Imaging has lodged a 510(k) submission for its InForm digital pathology device, moving the product from development into formal US regulatory assessment. FDA clearance is not assured, but a successful determination could open the door to commercial distribution in the company’s target market.

Booster has secured a further $7.4 million capital commitment for the Booster Innovation Fund, taking total committed and allocated capital above $23 million. The funding announcement arrives alongside disclosure of civil proceedings by New Zealand’s Financial Markets Authority and a new independent director.

FortifAI has emerged from its first year as an AI infrastructure company with $20.4 million in cash, but a $29 million statutory loss and sharply lower gaming revenue. The company now needs to turn NOL8’s early testing and partnerships into commercial adoption before its cash-backed growth strategy faces a harder test.

ClearVue Technologies reported just A$108,484 of FY2026 revenue against an A$11.86 million loss, while consuming A$8.69 million in operating cash. The solar-glazing developer says certifications, international partners and an 80-project pipeline have strengthened its platform, but the next test is converting those assets into cash revenue.

FBR has cut its annual loss dramatically and moved its first Mantis welding robot into commissioning, but year-end cash of just A$27,814 leaves the company dependent on fundraising, tax funding and successful delivery. Its audited accounts flag a material uncertainty over whether the robotics developer can continue as a going concern.